---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-25-000021"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:59:23.845571+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025

## Summary
- Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.
- Cash and equivalents $64.0M as of Dec 31, 2024; sufficient to fund into Q2 2026.
- Phase 1 trial of CMP-CPS-001 for UCDs ongoing; SAD completed safely, MAD dosing in progress; safety, PK, PD data expected Q4 2025.
- Phase 1b trial in female OTC heterozygotes expected Q2 2025 in Australia, Europe to follow.
- Development candidate CMP-SYNGAP-01 nominated for SYNGAP1-related disorders; GLP tox studies planned 2025.

## SEC filing metadata
- accession: 0001736730-25-000021
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/0001736730-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/camp-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-25-000021
- JSON: https://secwatch.observer/filing/0001736730-25-000021.json
- Plain text: https://secwatch.observer/filing/0001736730-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.